Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis

July 16, 2024

Ryan Haumschild, PharmD, MS, MBA
Heidi Crayton, MD

Opinion

Video

Medical experts discuss the failure of evobrutinib to meet its primary endpoint in phase 3 trials, review the primary outcomes of the phase 2B study of tolebrutinib in relapsing multiple sclerosis, examine payers' perspectives on the currently available data for tolebrutinib, and briefly describe the design of the HERCULES trial.

EP: 1.Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

EP: 2.Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression

EP: 3.Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis

EP: 4.Examining Key Unmet Needs in Multiple Sclerosis

EP: 5.Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies

EP: 6.MS Treatment Guidelines: Expert Insights on Updates and Decision-Making

EP: 7.Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment

EP: 8.Examining Challenges with Drug Switching and Step Therapy in MS Treatment

EP: 9.Typical Payer Coverage Criteria for Multiple Sclerosis Therapies

EP: 10.BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment

Now Viewing

EP: 11.Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis

EP: 12.Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies

EP: 13.Multiple Sclerosis: Looking Toward the Future

Video content above is prompted by the following questions:

Evobrutinib did not meet its primary endpoint in phase 3 trials. Were you surprised by these results?
What were the primary outcomes of the phase 2B study of tolebrutinib in relapsing multiple sclerosis?
- What was seen in the 3-year data?
- How do payers view the currently available data of tolebrutinib?
Tolebrutinib is also under investigation in non-relapsing secondary progressive multiple sclerosis. Why is there a need to investigate therapies in this phenotype and what is the phase 3 HERCULES trial design?